CD73 inhibitors and pharmaceutical uses thereof
CD73 (also known as ecto-5′-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I′ and pharmaceutically acceptable esters or salts thereof.
1 . A compound of Formula I′, or a pharmaceutically acceptable salt or ester thereof:
where:
W is oxygen; X′ is —P(═O)(OR′)—, wherein R′ is a hydrogen; Y is —PO 3 R′ 2 , wherein R′ is a hydrogen; R 1′ is a hydroxyl (—OH); R 2′ is chlorine (—Cl); and
R 3′ and R 4′ , together with the nitrogen atom to which they are attached, form a monocyclic, bicyclic, tricyclic, spiral-cyclic, or fused-cyclic system, wherein the cyclic system is substituted or unsubstituted.